Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

Nasus Pharma (NYSE: NSRX) will present at the virtual Life Sciences Investor Forum on March 11, 2026 at 12:30 p.m. ET.

Rhea-AI Summary

Nasus Pharma (NYSE: NSRX) will present at the virtual Life Sciences Investor Forum on March 11, 2026 at 12:30 p.m. ET.

CEO Dan Teleman will deliver the presentation and Nasus management will be available for one-on-one meetings during the March 11-12, 2026 conference hosted by VirtualInvestorConferences.com.

Argus Mar 9 session

-15.43% close to close Open Argus

Details

News Market Reaction – NSRX

On Mar 9, the day this news came out, NSRX closed 15.43% below the previous close.

Data tracked by StockTitan Argus for the Mar 9 session.

Market Context

On Mar 9, the day this news came out, the stock closed 15.4% below the previous close. A negative re...

Analysis

On Mar 9, the day this news came out, the stock closed 15.4% below the previous close. A negative reaction despite neutral conference news would fit a pattern where enthusiasm around NS002 and capital markets activity has not always been rewarded consistently, as seen after positive Phase 2 data. Recent increases in authorized share capital and private placement activity could heighten sensitivity to dilution or governance concerns. Past instances show that even fundamentally positive developments have sometimes been followed by selling pressure, underscoring event-driven volatility.

Key Figures

Conference dates: March 11–12, 2026 Presentation time: 12:30 p.m. ET

Conference dates

March 11–12, 2026

Life Sciences Investor Forum schedule

Presentation time

12:30 p.m. ET

NSRX company presentation slot on March 11, 2026

Historical Context

5 past events · Latest: Feb 20

5 events

1. Feb 20

   Investor conferences

   24h Move

   +18.0%

   Announced participation in three investor conferences with CEO presentations and meetings.

2. Feb 17

   Clinical data preview

   24h Move

   +1.0%

   Planned AAAAI 2026 posters on superior nasal deposition and stability for NS002.

3. Feb 13

   Private placement close

   24h Move

   +5.4%

   Closed $15.0M private placement of shares and warrants to fund NS002 and pipeline.

4. Feb 10

   Private placement pricing

   24h Move

   +2.9%

   Announced pricing of $15.0M private placement to support pivotal NS002 study.

5. Jan 20

   Phase 2 interim data

   24h Move

   -7.5%

   Reported positive interim Phase 2 NS002 PK and safety data versus EpiPen.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intranasal

1 terms

intranasal medical

"development of innovative intranasal products to treat emergency medical conditions"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that Company management will participate and present at the upcoming virtual Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com during March 11-12, 2026.

Presentation details

• Date and time: March 11, 2026, 12:30 p.m. ET
• Location: Virtual (Register HERE: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5270561/nasus-pharma-ltd-nyse-nsrx)
• Format: Company presentation
• Speaker: Dan Teleman, Chief Executive Officer

Nasus management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.

About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’ proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nasus Pharma (NSRX) present at the Life Sciences Investor Forum?

Nasus Pharma will present on March 11, 2026 at 12:30 p.m. ET. According to Nasus Pharma, CEO Dan Teleman is the scheduled speaker and the event is virtual as part of the March 11-12, 2026 Life Sciences Investor Forum.

Who is the speaker representing Nasus Pharma (NSRX) at the March 2026 conference?

The scheduled speaker is Dan Teleman, Chief Executive Officer. According to Nasus Pharma, management will also host one-on-one meetings during March 11-12, 2026 for investors and partners arranged via the conference representative.

How can investors register to attend the Nasus Pharma (NSRX) presentation on March 11, 2026?

Investors can register via the conference platform's registration link provided by the host. According to Nasus Pharma, attendees should use VirtualInvestorConferences.com registration and contact their conference representative to arrange one-on-one meetings.

Will Nasus Pharma (NSRX) offer one-on-one meetings during the Life Sciences Investor Forum?

Yes, Nasus management will be available for one-on-one meetings during March 11-12, 2026. According to Nasus Pharma, interested parties must contact their conference representative to schedule meetings with company management.

Where is the Life Sciences Investor Forum presentation by Nasus Pharma (NSRX) being hosted?

The presentation is hosted virtually by VirtualInvestorConferences.com on March 11-12, 2026. According to Nasus Pharma, the March 11 session at 12:30 p.m. ET will be delivered by CEO Dan Teleman and is accessible online via registration.